143 results on '"Kanao, Kent"'
Search Results
102. PD15-01 CHARACTERIZING THE DOMINANT/INDEX LESION IN PROSTATE CANCER: IMPLICATIONS FOR GRADING AND STAGING
- Author
-
Matsumoto, Kazuhiro, primary, Kanao, Kent, additional, Udo, Kazuma, additional, Al-Ahmadie, Hikmat, additional, Chen, Ying-bei, additional, Gopalan, Anuradha, additional, Tickoo, Satish, additional, Reuter, Victor, additional, and Fine, Samson, additional
- Published
- 2014
- Full Text
- View/download PDF
103. The Predictive Value of C-reactive Protein for Prognosis in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Multi-institutional Study
- Author
-
Tanaka, Nobuyuki, primary, Kikuchi, Eiji, additional, Shirotake, Suguru, additional, Kanao, Kent, additional, Matsumoto, Kazuhiro, additional, Kobayashi, Hiroaki, additional, Miyazaki, Yasumasa, additional, Ide, Hiroki, additional, Obata, Jun, additional, Hoshino, Katsura, additional, Hayakawa, Nozomi, additional, Ito, Yujiro, additional, Kosaka, Takeo, additional, Kodaira, Kiichiro, additional, Oyama, Masafumi, additional, Miyajima, Akira, additional, Momma, Tetsuo, additional, Nakagawa, Ken, additional, Ueno, Munehisa, additional, and Oya, Mototsugu, additional
- Published
- 2014
- Full Text
- View/download PDF
104. Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location
- Author
-
Tanaka, Nobuyuki, primary, Kikuchi, Eiji, additional, Kanao, Kent, additional, Matsumoto, Kazuhiro, additional, Kobayashi, Hiroaki, additional, Ide, Hiroki, additional, Miyazaki, Yasumasa, additional, Obata, Jun, additional, Hoshino, Katsura, additional, Shirotake, Suguru, additional, Akita, Hirotaka, additional, Kosaka, Takeo, additional, Miyajima, Akira, additional, Momma, Tetsuo, additional, Nakagawa, Ken, additional, Hasegawa, Shintaro, additional, Nakajima, Yosuke, additional, Jinzaki, Masahiro, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
105. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy
- Author
-
Hattori, Seiya, primary, Kosaka, Takeo, additional, Mizuno, Ryuichi, additional, Kanao, Kent, additional, Miyajima, Akira, additional, Yasumizu, Yota, additional, Yazawa, Satoshi, additional, Nagata, Hirohiko, additional, Kikuchi, Eiji, additional, Mikami, Shuji, additional, Jinzaki, Masahiro, additional, Nakagawa, Ken, additional, Tanimoto, Akihiro, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
106. 398 CHARACTERISTICS AND OUTCOME IN METASTATIC UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL EXPERIENCE
- Author
-
Tanaka, Nobuyuki, primary, Kikuchi, Eiji, additional, Shirotake, Suguru, additional, Matsumoto, Kazuhiro, additional, Kobayashi, Hiroaki, additional, Miyazaki, Yasumasa, additional, Ide, Hiroki, additional, Obata, Jun, additional, Hoshino, Katsura, additional, Kosaka, Takeo, additional, Kanao, Kent, additional, Miyajima, Akira, additional, Momma, Tetsuo, additional, Nakagawa, Ken, additional, Nakajima, Yosuke, additional, Hasegawa, Shintaro, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
107. 697 C-REACTIVE PROTEIN INDEPENDENTLY PREDICTS THE PROGNOSIS OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH RADICAL NEPHROURETERECTOMY: A MULTI-INSTITUTIONAL STUDY
- Author
-
Obata, Jun, primary, Kikuchi, Eiji, additional, Tanaka, Nobuyuki, additional, Ishioka, Katsura, additional, Shirotake, Suguru, additional, Matsumoto, Kazuhiro, additional, Kobayashi, Hiroaki, additional, Miyazaki, Yasumasa, additional, Ide, Hiroki, additional, Hayakawa, Nozomi, additional, Ito, Yujiro, additional, Kanao, Kent, additional, Miyajima, Akira, additional, Momma, Tetsuo, additional, Nakagawa, Ken, additional, Ueno, Munehisa, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
108. 399 PREDICTIVE VALUE OF POSITIVE URINE CYTOLOGY FOR PROGNOSIS IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY
- Author
-
Tanaka, Nobuyuki, primary, Kikuchi, Eiji, additional, Miyazaki, Yasumasa, additional, Shirotake, Suguru, additional, Kobayashi, Hiroaki, additional, Matsumoto, Kazuhiro, additional, Ide, Hiroki, additional, Obata, Jun, additional, Hoshino, Katsura, additional, Kosaka, Takeo, additional, Kanao, Kent, additional, Oyama, Masafumi, additional, Miyajima, Akira, additional, Momma, Tetsuo, additional, Nakagawa, Ken, additional, Nakajima, Yosuke, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
109. 1165 NOVEL ALGORITHM FOR PREDICTING SEVERE CASES OF ACUTE BACTERIAL PROSTATITIS
- Author
-
Yazawa, Satoshi, primary, Nagata, Hirohiko, additional, Kanao, Kent, additional, Kikuchi, Eiji, additional, Hosokawa, Naoto, additional, Hongo, Shu, additional, Ohji, Goh, additional, Morita, Shinya, additional, Kosaka, Takeo, additional, Kono, Hidaka, additional, Mizuno, Ryuichi, additional, Asanuma, Hiroshi, additional, Miyajima, Akira, additional, Nakagawa, Ken, additional, Tanoguchi, Hitoshi, additional, Nakajima, Yosuke, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
110. 681 THE DISTINCT ASSOCIATION BETWEEN PRIMARY TUMOR LOCATION AND THE PATTERNS OF METASTATIC SPREAD FOLLOWING RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
- Author
-
Tanaka, Nobuyuki, primary, Kikuchi, Eiji, additional, Kanao, Kent, additional, Matsumoto, Kazuhiro, additional, Kobayashi, Hiroaki, additional, Ide, Hiroki, additional, Miyazaki, Yasumasa, additional, Obata, Jun, additional, Hoshino, Katsura, additional, Shirotake, Suguru, additional, Kosaka, Takeo, additional, Miyajima, Akira, additional, Momma, Tetsuo, additional, Nakajima, Yosuke, additional, Hasegawa, Shintaro, additional, Nakagawa, Ken, additional, Jinzaki, Masahiro, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
111. THREE CASES OF IgG4-RELATED DISEASE ASSOCIATED WITH URINARY TRACT OBSTRUCTION
- Author
-
Yazawa, Satoshi, primary, Ohara, Rei, additional, Maeda, Takahiro, additional, Kanao, Kent, additional, Hattori, Seiya, additional, Nakajima, Yosuke, additional, and Oya, Mototsugu, additional
- Published
- 2013
- Full Text
- View/download PDF
112. Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study
- Author
-
Vargas, Hebert Alberto, primary, Akin, Oguz, additional, Shukla-Dave, Amita, additional, Zhang, Jingbo, additional, Zakian, Kristen L., additional, Zheng, Junting, additional, Kanao, Kent, additional, Goldman, Debra A., additional, Moskowitz, Chaya S., additional, Reuter, Victor E., additional, Eastham, James A., additional, Scardino, Peter T., additional, and Hricak, Hedvig, additional
- Published
- 2012
- Full Text
- View/download PDF
113. 100 PREDICTIVE VALUES FOR NEPHRECTOMY AGAINST BLUNT RENAL TRAUMA: SINGLE INSTITUTE ANALYSIS OF 182 JAPANESE PATIENTS
- Author
-
Yazawa, Satoshi, primary, Nakajima, Yosuke, additional, Kanao, Kent, additional, Ohara, Rei, additional, Kitano, Mitsuhide, additional, Yoshii, Hiroshi, additional, and Oya, Mototsugu, additional
- Published
- 2012
- Full Text
- View/download PDF
114. Transurethral lithotripsy with holmium-YAG laser of a large exogenous prostatic calculus
- Author
-
Hasegawa, Masanori, primary, Ohara, Rei, additional, Kanao, Kent, additional, and Nakajima, Yosuke, additional
- Published
- 2010
- Full Text
- View/download PDF
115. 301 THE IMPACT OF POSITIVE CORE DENSITY ON PREDICTION OF THE PRETREATMENT STAGE OF PROSTATE CANCER
- Author
-
Kanao, Kent, primary, Kono, Hidaka, additional, Mizuno, Ryuichi, additional, Hirohiko, Nagata, additional, Kikuchi, Eiji, additional, Miyajima, Akira, additional, Nakagawa, Ken, additional, and Mototsugu, Oya, additional
- Published
- 2010
- Full Text
- View/download PDF
116. PSA CUT-OFF NOMOGRAM THAT AVOID OVER-DETECTION OF PROSTATE CANCER IN ELDERLY MEN
- Author
-
Kanao, Kent, primary, Komori, Osamu, additional, Nakashima, Jun, additional, Ohigashi, Takashi, additional, Kikuchi, Eiji, additional, Miyajima, Akira, additional, Nakagawa, Ken, additional, Eguchi, Shinto, additional, and Oya, Mototsugu, additional
- Published
- 2009
- Full Text
- View/download PDF
117. WS1-1-5 Reduced Acetylation of Histone h3 in Renal Cell Carcinoma : a Potential Target of Histone Deacetylase Inhibitors(Renal Cell Cancer)
- Author
-
Kanao, Kent, primary, Mikami, Shuji, additional, Mizuno, Ryuichi, additional, Shinojima, Toshiaki, additional, and Oya, Mototsugu, additional
- Published
- 2008
- Full Text
- View/download PDF
118. 447: Reduced Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacelase Inhibitors
- Author
-
Kanao, Kent, primary, Oya, Mototsugu, additional, Mikami, Shuji, additional, Mizuno, Ryuichi, additional, Shinojima, Toshiaki, additional, and Murai, Masaru, additional
- Published
- 2007
- Full Text
- View/download PDF
119. Prevention of Cancer Cachexia by a Novel Nuclear Factor κB Inhibitor in Prostate Cancer
- Author
-
Kuroda, Kenji, primary, Horiguchi, Yutaka, additional, Nakashima, Jun, additional, Kikuchi, Eiji, additional, Kanao, Kent, additional, Miyajima, Akira, additional, Ohigashi, Takashi, additional, Umezawa, Kazuo, additional, and Murai, Masaru, additional
- Published
- 2005
- Full Text
- View/download PDF
120. PROSTATE SPECIFIC ANTIGEN ADJUSTED FOR TRANSITION ZONE EPITHELIAL VOLUME: THE POWERFUL PREDICTOR FOR THE DETECTION OF PROSTATE CANCER ON REPEAT BIOPSY
- Author
-
OHIGASHI, TAKASHI, primary, KANAO, KENT, additional, KIKUCHI, EIJI, additional, NAKAGAWA, KEN, additional, NAKASHIMA, JUN, additional, MARUMO, KEN, additional, and MURAI, MASARU, additional
- Published
- 2005
- Full Text
- View/download PDF
121. 1477: Prostate Specific Antigen Adjusted for Transition Zone Epithelial Volume is the Most Powerful Predictor for the Detection of Prostate Cancer on Repeat Biopsy
- Author
-
Ohigashi, Takashi, primary, Kanao, Kent, additional, Nakashima, Jun, additional, Marumo, Ken, additional, and Murai, Masaru, additional
- Published
- 2005
- Full Text
- View/download PDF
122. Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment.
- Author
-
Nakamura, Kogenta, Ikawa, Kazuro, Nishikawa, Genya, Kobayashi, Ikuo, Tobiume, Motoi, Sugie, Miho, Muramatsu, Hiroyuki, Morinaga, Shingo, Kajikawa, Keishi, Watanabe, Masahito, Kanao, Kent, Onita, Tetsushu, and Morikawa, Norifumi
- Subjects
- *
BENIGN prostatic hyperplasia , *PROSTATE , *TRANSURETHRAL prostatectomy , *PROSTATITIS , *PHARMACOKINETICS - Abstract
Flomoxef is used to treat bacterial prostatitis; however, its prostatic pharmacokinetics have not been fully clarified. Flomoxef (500 or 1000 mg) was administered to patients with benign prostatic hypertrophy (n = 54). After a 0.5-h infusion, venous blood samples were drawn at time points of 0.5–5 h, and prostate tissue samples were collected at time points of 0.5–1.5 h during transurethral resection of the prostate. The drug concentrations in plasma and prostate tissue were analyzed pharmacokinetically and used for a stochastic simulation to predict the probability of attaining pharmacodynamic target in prostate tissue. Showing dose linearity in the prostatic pharmacokinetics, flomoxef rapidly penetrated into prostate tissue, with a prostate/plasma ratio of 0.48–0.50 (maximum drug concentration) and 0.42–0.55 (area under the drug concentration-time curve). Against the tested populations of Escherichia coli , Klebsiella and Proteus species isolates, 0.5-h infusion of 1000 mg three times daily achieved a ≥90% expected probability of attaining the bactericidal target (70% of the time above the minimum inhibitory concentration [MIC]) in prostate tissue. The site-specific pharmacodynamic-based breakpoint (the highest MIC at which the target-attainment probability in prostate tissue was >90%) values were 0.25 mg/L (MIC for 90th percentile of E. coli and Klebsiella species) for 500 mg four times daily and 0.5 mg/L (MIC 90 of Proteus species) for 1000 mg four times daily. These results help to fully characterize the prostatic pharmacokinetics of flomoxef, while also helping to rationalize and optimize the dosing regimens for prostatitis based on site-specific pharmacodynamic target attainment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
123. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.
- Author
-
Nakamura, Kogenta, Ikawa, Kazuro, Nishikawa, Genya, Kobayashi, Ikuo, Narushima, Masahiro, Muramatsu, Hiroyuki, Morinaga, Shingo, Kajikawa, Keishi, Kato, Yoshiharu, Watanabe, Masahito, Zennami, Kenji, Kanao, Kent, Morikawa, Norifumi, and Sumitomo, Makoto
- Subjects
- *
FLUOROQUINOLONES , *PROSTATE diseases , *PHARMACOKINETICS , *PHARMACODYNAMICS , *CLINICAL trials , *DRUG dosage , *THERAPEUTICS - Abstract
The present study examined the clinical pharmacokinetics of pazufloxacin in prostate tissue and estimated the probability of target attainment for tissue-specific pharmacodynamic goals related to treating prostatitis using various intravenous dosing regimens. Patients with prostatic hypertrophy received prophylactic infusions of pazufloxacin (500 mg, n = 23; 1000 mg, n = 25) for 0.5 h prior to transurethral prostate resection. Drug concentrations in plasma (0.5–5 h) and prostate tissue (0.5–1.5 h) were measured by high-performance liquid chromatography and used for subsequent noncompartmental and three-compartmental analysis. Monte Carlo simulation was performed to evaluate the probability of target attainment of a specific minimum inhibitory concentration (MIC) in prostate tissue: the proportion that achieved both area under the drug concentration over time curve (AUC)/MIC = 100 and maximum concentration (C max )/MIC = 8. Prostatic penetration of pazufloxacin was good with mean C max ratios (prostate tissue/plasma) of 0.82–0.99 and for AUC, 0.80–0.98. The probability of reaching target MIC concentrations in prostate tissue was more than 90% for dosing schedules of 0.25 mg/L for 500 mg every 24 h (500 mg daily), 0.5 mg/L for 500 mg every 12 h (1000 mg daily), 1 mg/L for 1000 mg every 24 h (1000 mg daily), and 2 mg/L for 1000 mg every 12 h (2000 mg daily). Importantly, the 2000 mg daily regimen of pazufloxacin produced a profile sufficient to have an antibacterial effect in prostate tissue against clinical isolates of Escherichia coli and Klebsiella pneumonia with MIC values less than 2 mg/L. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
124. Novel algorithm for management of acute epididymitis.
- Author
-
Hongo, Hiroshi, Kikuchi, Eiji, Matsumoto, Kazuhiro, Yazawa, Satoshi, Kanao, Kent, Kosaka, Takeo, Mizuno, Ryuichi, Miyajima, Akira, Saito, Shiro, and Oya, Mototsugu
- Subjects
- *
EPIDIDYMITIS , *LEUKOCYTE count , *C-reactive protein , *MEDICAL decision making , *SEVERITY of illness index , *THERAPEUTICS - Abstract
Objectives To identify predictive factors for the severity of epididymitis and to develop an algorithm guiding decisions on how to manage patients with this disease. Methods A retrospective study was carried out on 160 epididymitis patients at Keio University Hospital. We classified cases into severe and non-severe groups, and compared clinical findings at the first visit. Based on statistical analyses, we developed an algorithm for predicting severe cases. We validated the algorithm by applying it to an external cohort of 96 patients at Tokyo Medical Center. The efficacy of the algorithm was investigated by a decision curve analysis. Results A total of 19 patients (11.9%) had severe epididymitis. Patient characteristics including older age, previous history of diabetes mellitus and fever, as well as laboratory data including a higher white blood cell count, C-reactive protein level and blood urea nitrogen level were independently associated with severity. A predictive algorithm was created with the ability to classify epididymitis cases into three risk groups. In the Keio University Hospital cohort, 100%, 23.5%, and 3.4% of cases in the high-, intermediate-, and low-risk groups, respectively, became severe. The specificity of the algorithm for predicting severe epididymitis proved to be 100% in the Keio University Hospital cohort and 98.8% in the Tokyo Medical Center cohort. The decision curve analysis also showed the high efficacy of the algorithm. Conclusions This algorithm might aid in decision-making for the clinical management of acute epididymitis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
125. Penetration of piperacillin–tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
- Author
-
Kobayashi, Ikuo, Ikawa, Kazuro, Nakamura, Kogenta, Nishikawa, Genya, Kajikawa, Keishi, Yoshizawa, Takahiko, Watanabe, Masahito, Kato, Yoshiharu, Zennami, Kenji, Kanao, Kent, Tobiume, Motoi, Yamada, Yoshiaki, Mitsui, Kenji, Narushima, Masahiro, Morikawa, Norifumi, and Sumitomo, Makoto
- Subjects
- *
PIPERACILLIN , *PENICILLIN , *TAZOBACTAM , *BETA-lactamase inhibitors , *PROSTATE - Abstract
This study aimed to investigate the penetration of PIPC–TAZ into human prostate, and to assess effectiveness of PIPC–TAZ against prostatitis by evaluating site-specific PK–PD. Patients with prostatic hypertrophy ( n = 47) prophylactically received a 0.5 h infusion of PIPC–TAZ (8:1.2–0.25 g or 4–0.5 g) before transurethral resection of the prostate. PIPC–TAZ concentrations in plasma (0.5–5 h) and prostate tissue (0.5–1.5 h) were analyzed with a three-compartment PK model. The estimated model parameters were, then used to estimate the drug exposure time above the minimum inhibitory concentration for bacteria ( T > MIC, the PD indicator for antibacterial effects) in prostate tissue for six PIPC–TAZ regimens (2.25 or 4.5 g; once, twice, three times or four times daily; 0.5 h infusions). Prostate tissue/plasma ratio of PIPC was about 36% both for the maximum drug concentration ( C max ) and the area under the drug concentration–time curve (AUC). Against MIC distributions for isolates of Escherichia coli , Klebsiella species and Proteus species, regimens of 4.5 g twice daily and 2.25 g three times daily achieved a >90% probability of attaining the bacteriostatic target for PIPC (30% T > MIC) in prostate tissue; regimens of 4.5 g three times daily and 2.25 g four times daily achieved a >90% probability of attaining the bactericidal target for PIPC (50% T > MIC) in prostate tissue. However, against Pseudomonas aeruginosa isolates, none of the tested regimens achieved a >90% probability. PIPC–TAZ is appropriate for the treatment of prostatitis from the site-specific PK–PD perspective. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
126. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: A multi-institutional study 1 [1] This work was supported in part by Grants-in-Aid for Scientific Research (#24791671 to Tanaka N.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
- Author
-
Tanaka, Nobuyuki, Kikuchi, Eiji, Kanao, Kent, Matsumoto, Kazuhiro, Shirotake, Suguru, Kobayashi, Hiroaki, Miyazaki, Yasumasa, Ide, Hiroki, Obata, Jun, Hoshino, Katsura, Hayakawa, Nozomi, Kosaka, Takeo, Oyama, Masafumi, Miyajima, Akira, Momma, Tetsuo, Nakagawa, Ken, Jinzaki, Masahiro, Nakajima, Yosuke, and Oya, Mototsugu
- Subjects
- *
NEPHRECTOMY , *TRANSITIONAL cell carcinoma , *CYTOLOGY , *URINARY organ cancer , *METASTASIS , *CANCER relapse , *PATIENTS , *THERAPEUTICS - Abstract
Abstract: Background and objective: Few studies have addressed the predictive value of positive urine cytology for prognosis in patients with upper tract urothelial carcinoma (UTUC). We investigated whether the status of preoperative urine cytology could provide additional prognostic information following radical nephroureterectomy (RNU). Materials and methods: The study included 474 patients with primary nonmetastatic UTUC (pTa-4N0M0) from a retrospective multi-institutional cohort. The median follow-up period was 35 months. Associations between the status of urine cytologic evaluation and outcomes were analyzed using multivariate Cox regression models. Urine cytology was evaluated preoperatively using voided samples. Disease recurrence was defined as any relapse in nonbladder lesions and was coded separately from intravesical recurrence. Results: Positive urine cytology was detected in 184 patients (38.8%) preoperatively. Disease recurrence occurred in 127 patients, while intravesical recurrence occurred in 219 patients; 83 patients died of UTUC during follow-up. Kaplan-Meier analysis revealed that only the incidence of intravesical recurrence was significantly associated with the status of urine cytologic evaluation (P = 0.024); the intravesical recurrence-free survival rates at 1 and 3 years following RNU were 61.4% and 46.2% in patients with positive urine cytology and 71.1% and 51.6% in their counterparts, respectively. Multivariate analysis showed that gender (hazard ratio [HR] = 1.74, 95% confidence interval [CI]; 1.28–2.43), tumor multifocality in RNU specimens (HR = 1.64, 95% CI; 1.09–2.47), and positive urine cytology (HR = 1.41, 95% CI; 1.08–1.85) were independent risk factors for subsequent intravesical recurrence. Conclusions: The results showed the prognostic value of positive urine cytology in patients with primary UTUC, and preoperative positive urine cytology may be associated with a significant increase in the prevalence of intravesical recurrence following RNU. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
127. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
- Author
-
Tamura, Keita, Ando, Ryosuke, Takahara, Kiyoshi, Ito, Toshiki, Kanao, Kent, Yasui, Takahiro, Shiroki, Ryoichi, and Miyake, Hideaki
- Subjects
- *
NEUTROPHIL lymphocyte ratio , *RENAL cell carcinoma , *C-reactive protein , *METASTASIS , *KARNOFSKY Performance Status , *RESEARCH , *MATHEMATICAL models , *RESEARCH methodology , *RETROSPECTIVE studies , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *LYMPHOCYTES , *NEUTROPHILS , *COMPARATIVE studies , *DRUG therapy , *KIDNEY tumors , *THEORY , *LEUKOCYTE count - Abstract
Purpose: The objective of this study was to develop a novel prognostication model in patients with treatment-naïve metastatic renal cell carcinoma (mRCC).Methods: This study included 325 consecutive mRCC patients receiving first-line molecular-targeted therapy at 4 institutions. Potential parameters associated with overall survival (OS) in these patients were investigated to develop a novel stratification model.Results: Median OS of the 325 patients was 38 months. A multivariable analysis of several factors identified independent predictors associated with unfavorable OS as follows: no previous nephrectomy, Karnofsky performance status <80%, albumin (Alb) ≤3.5 g/dl, C-reactive protein (CRP) >0.5 mg/dl and neutrophil-to-lymphocyte ratio (NLR) >3. Of these 5 independent OS predictors, 3 numeric factors were used to develop the ACN (Alb, CRP, and NLR) model by dividing patients into 3 groups according to the positive numbers of these 3 numeric risk factors. Median OS durations were 63, 37, and 11 months in the favorable (n = 105, 32.3%, without risk factors), intermediate (n = 88, 27.1%, with a single risk factor), and poor (n = 132, 40.6%, with multiple risk factors) risk groups, respectively. The ACN model as a prognostication tool was shown to be superior to the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models by both the concordance index and decision curve analysis.Conclusions: The ACN model could stratify the prognostic risk of mRCC patients receiving first-line targeted therapy more accurately than the MSKCC and IMDC models. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
128. Choroidal Metastasis From Papillary Renal Cell Carcinomas: A Case Report and a Review of the Literature.
- Author
-
Hiruta S, Kaneko G, Miyama Y, Miyasaka Y, Umezawa Y, Hagiwara M, Shirotake S, Kanao K, Yasuda M, and Oyama M
- Abstract
Choroidal metastasis originating from renal cell carcinomas (RCCs) is rare. To the best of our knowledge, 31 cases of choroidal metastasis from RCC have been reported in the English literature as of January 31, 2024. Nevertheless, physicians need to be vigilant in recognizing this condition, as its progression impacts the quality of life (QOL) of affected patients. In Case 1, a 60-year-old male with a medical history of papillary RCC experienced a deterioration in visual acuity (VA) and was diagnosed with solitary choroidal metastasis. Subsequently, multiple metastases were identified, prompting the initiation of a combination therapy regimen consisting of pembrolizumab plus axitinib. Despite treatment, progression of choroidal metastasis and a further decline in VA were observed. The patient underwent stereotactic radiotherapy and experienced complete resolution of the choroidal metastasis, accompanied by a slight improvement in VA. In Case 2, a 76-year-old man presented with a renal tumor accompanied by lung metastases. He underwent nephrectomy, and the histological diagnosis was papillary RCC. We initiated combination therapy consisting of nivolumab plus cabozantinib. The patient experienced a decrease in VA during treatment. We identified extensive fine metastases scattered throughout the bilateral choroid. We administered axitinib, but the patient experienced bilateral blindness. Given the absence of established therapy for choroidal metastasis, it is crucial to maintain flexibility in treatment selection. Local or systemic approaches should be used as deemed appropriate for each individual case., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Hiruta et al.)
- Published
- 2024
- Full Text
- View/download PDF
129. Aggressive variant prostate cancer with multiple subcutaneous metastases: a case report.
- Author
-
Hoshino Y, Kanao K, Miyama Y, Kosaka T, Kaneko G, Shirotake S, Yasuda M, and Oyama M
- Abstract
A 71-year-old man with bone metastasis of hormone-sensitive prostate cancer was treated with androgen deprivation therapy and apalutamide. Radium-223 and radiation therapy were administered after it become castration resistant. Although prostate-specific antigen levels remained low, multiple subcutaneous metastases of neuroendocrine prostate cancer were observed. A review of the pre-treatment prostate needle biopsy revealed a small component with features suggestive of neuroendocrine differentiation. Phosphatase and tensine homolog loss and tumor protein p53 overexpression were observed, confirming the diagnosis of aggressive variant prostate cancer. Platinum-based chemotherapy was administered; however, the patient died 28 months after diagnosis. In this case, if the diagnosis of aggressive variant prostate cancer had been made at an earlier time by biopsy specimens, there might have been a possibility to improve the prognosis by the earlier introduction of the platinum-based regimen., Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-024-00673-7., Competing Interests: Conflict of interestThe authors declare that they have no conflict of interest., (© The Author(s) 2024.)
- Published
- 2024
- Full Text
- View/download PDF
130. New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma.
- Author
-
Saito T, Kanao K, Matsumoto K, Fukumoto K, Igarashi D, Takahashi T, Kaneko G, Shirotake S, Nishimoto K, Mizuno R, Ishida M, Hara S, Oya M, and Oyama M
- Abstract
Objectives: We aim to evaluate the risk of recurrence after neoadjuvant chemotherapy followed by radical cystectomy, particularly in ypT2 disease in patients with urothelial carcinoma, because it is not clear if all eligible patients with high-risk muscle-invasive urothelial carcinoma should be treated with adjuvant nivolumab., Materials and Methods: We analysed the radiological and clinicopathological features, including cT and ypT stages, of 197 patients who had undergone two to four cycles of cisplatin-based neoadjuvant chemotherapy and radical cystectomy without adjuvant chemotherapy. We stratified the risk of postoperative recurrence by these factors., Results: The median observation period was 29.6 (interquartile range, 11.4-71.7) months, and disease recurrence was observed in 58 patients. Multivariate analysis revealed that ypT stage ( P = 0.019) and lymphovascular invasion ( P = 0.015) were independent risk factors for postoperative recurrence. The ypT2 group ( n = 38) had significantly better recurrence-free survival than the ypT3 group ( n = 41) (median recurrence-free survival: not reached vs. 13.4 months, respectively, P = 0.005). In ypT2 disease, the cT2 and ypT2 group ( n = 15), which was diagnosed as cT2 preoperatively and then diagnosed as ypT2 postoperatively, had significantly better recurrence-free survival than the cT3/4 and ypT2 group ( n = 23) (median recurrence-free survival: not reached vs. 63.1 months, respectively, P = 0.034). There was no significant difference in recurrence-free survival between the ypT ≤ 1 ( n = 106) and the cT2 and ypT2 groups (median recurrence-free survival: not reached in both, P = 0.962)., Conclusion: Patients with cT2 and ypT2 stage have a relatively low risk of recurrence and thus have a lower need for adjuvant nivolumab, particularly those with ypT2., Competing Interests: All authors have no conflict of interest to disclose., (© 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.)
- Published
- 2023
- Full Text
- View/download PDF
131. Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
- Author
-
Kanao K, Takahashi T, Umezawa Y, Okabe T, Kaneko G, Shirotake S, Nishimoto K, and Oyama M
- Subjects
- Humans, Male, Androgen Antagonists therapeutic use, Androgens, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostate-Specific Antigen therapeutic use, Retrospective Studies, Treatment Outcome, Abiraterone Acetate therapeutic use, Prostatic Neoplasms pathology
- Abstract
Background: The treatment landscape for men with metastatic hormone-naïve prostate cancer (mHNPC) has dramatically changed with the approval of next-generation anti-androgen drugs. We compared the treatment efficacy of abiraterone with that of combined androgen blockade (CAB) therapy and androgen deprivation therapy (ADT) alone in men with high-risk mHNPC., Methods: In total, 146 Japanese men with high-risk mHNPC were retrospectively analyzed. As initial hormonal therapy, 30, 83, and 33 men were treated with ADT plus abiraterone (ABI group), ADT plus bicalutamide (CAB group), and ADT alone (ADT group), respectively. Treatment efficacy was compared using time to castration resistance (TTCR) and prostate-specific antigen (PSA) response among the groups. Propensity score matching analysis was also performed to adjust for baseline differences., Results: The median (95% confidence interval [CI]) TTCR in the ABI, CAB, and ADT groups were not reached, 10.7 (7.6-13.8) months and 11.0 (7.9-12.4) months, respectively, and it was significantly longer in the ABI group than in the other groups (p = 0.0012, p = 0.0008). In propensity score matching analysis, the median TTCR was also significantly longer in the ABI group than in the other groups (hazard ratio [HR], 0.47; 95% CI, 0.22-0.98; p = 0.010; HR, 0.32; 95% CI, 0.12-0.85; p = 0.004). The number of men who achieved PSA levels ≤0.2 ng/mL after propensity score matching were significantly higher in the ABI group than in the other groups., Conclusions: Our results provide important evidence regarding the superiority of abiraterone over CAB therapy and ADT alone for initial treatment for men with newly diagnosed mHNPC., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
132. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.
- Author
-
Miyama Y, Kanao K, Uranishi K, Hirasaki M, and Yasuda M
- Abstract
In advanced urothelial carcinoma (UC), approximately 20% of patients respond to pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody. Herein, we reported a single case of UC showing coexistence of sarcomatoid subtype and glandular differentiation. Notably, only glandular differentiation was recurrent, probably progressive, and metastatic, which showed complete response to pembrolizumab. An 80-year-old woman presented with hematuria and dysuria, and an intra-vesical tumor was detected on ultrasound. Transurethral resections (TUR) were performed three times. In the first TUR, a sub-pedunculated tumor and a flat lesion were closely but independently located. Pathologically, the sub-pedunculated tumor was an invasive UC, sarcomatoid subtype. Meanwhile, the flat lesion was invasive UC with glandular differentiation. Despite the second and the additional TUR, the tumor was growing and a lymph node metastasis was detected. The third TUR specimen showed UC with glandular differentiation, and a positive PD-L1 expression as well as high density CD8-positive lymphocytic cells infiltration were observed. Pembrolizumab was administered for four courses after terminating the chemotherapy. The CT scan revealed shrinkage of both primary tumor and metastases. Cystectomy and lymph nodes dissection were performed, and no residual carcinoma was detected. The therapeutic effect was regarded as pathological complete response. Pembrolizumab could be effective for special subtype or divergent differentiation of UC, particularly in an event of an 'immune hot' tumor., Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-022-00568-5., Competing Interests: Conflict of interestAll authors have no conflict of interests to declare., (© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
- Published
- 2022
- Full Text
- View/download PDF
133. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
- Author
-
Shirotake S, Miyama YU, Baba Y, Tajima H, Okada Y, Nakazawa K, Usami Y, Yasuda M, Igarashi D, Kaneko GO, Kanao K, Oyama M, and Nishimoto K
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Cytoreduction Surgical Procedures, Female, Humans, Ipilimumab adverse effects, Male, Nephrectomy, Nivolumab adverse effects, Retrospective Studies, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell etiology, Kidney Neoplasms drug therapy
- Abstract
Background/aim: CheckMate 214 study revealed that nivolumab plus ipilimumab combination therapy showed a strong and durable effect compared to sunitinib for patients with advanced renal cell carcinoma (aRCC). Most of the patients underwent previous nephrectomy before systemic treatment. We retrospectively investigated the clinical outcomes of Japanese patients treated with cytoreductive nephrectomy following nivolumab plus ipilimumab for aRCC., Patients and Methods: Seventy-nine patients were treated with systemic therapy for aRCC between October 2018 and August 2021 at the Saitama Medical University International Medical Center. Ten of 61 patients treated with nivolumab plus ipilimumab underwent cytoreductive nephrectomy after the combined immunotherapy., Results: The median overall survival and progression-free survival were 24.3 and 15.9 months, respectively. The objective response rate was 50.8%; 9.8% of patients had a complete response, and the median time to objective response was 3.2 (range=1.3-19.7) months. The estimated percentage of patients who sustained an objective response at 30 months was 73.0%. Twenty-three patients (74%) in the complete or partial response (CR/PR) group, 11 patients (52%) in the stable disease (SD) group, and two patients (22%) in the progressive disease (PD) group had immune-related adverse events of grade 3 or higher, respectively. For all 10 patients, cytoreductive nephrectomy following nivolumab plus ipilimumab treatment were completed safely. Three patients achieved a pathological complete response without viable cancer cells. Only two patients had residual lesions on images after deferred cytoreductive nephrectomy; the remaining patients achieved radiological CR., Conclusion: Cytoreductive nephrectomy after nivolumab plus ipilimumab treatment could be useful in a limited number of cases, possibly resulting in curative nephrectomy due to the durable therapeutic effect of immunotherapy., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
134. Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis.
- Author
-
Goto Y, Kanao K, Matsumoto K, Kobayashi I, Kajikawa K, and Onishi M
- Abstract
An 80 year old Japanese man with bilateral ureteral cancer underwent laparoscopic bilateral nephroureterectomy and lymph-node dissection. The pathological stage of the left and right ureteral tumors was pT3pN0M0. He received two courses of adjuvant gemcitabine and cisplatin chemotherapy while undergoing hemodialysis. The standard dose of gemcitabine and 50% of the standard dose of cisplatin were administered on the same day. Hemodialysis was started 6 h after gemcitabine administration and 1 h after cisplatin administration. The side effects were evaluated according to the Common Terminology Criteria for Adverse Events v4.0. In the first course, Grade 4 side effects including leukopenia, neutropenia, and thrombocytopenia were observed. He was treated with granulocyte colony-stimulating factor and platelet transfusion. Because the second course was administered without reducing the doses, granulocyte colony-stimulating factor was administered prophylactically, and Grade 4 side effects were reduced to Grade 3. Gemcitabine plus cisplatin chemotherapy can be administered safely in a patient with advanced ureteral cancer undergoing hemodialysis by adequately managing adverse events., Competing Interests: Conflict of interestThe authors declare that they have no conflict of interest., (© The Author(s) 2021.)
- Published
- 2021
- Full Text
- View/download PDF
135. Reduced port laparoscopic radical nephrectomy using an umbilical zigzag skin incision for renal cell carcinoma.
- Author
-
Kaneko G, Shirotake S, Kanao K, and Oyama M
- Abstract
Reduced port laparoscopic radical nephrectomy (RPLRN) is an equivalent approach to conventional laparoscopic radical nephrectomy (LRN). In LRN, one wound generally needs to be extended for specimen extraction; therefore, some ingenuity is needed to achieve a good cosmetic outcome. We herein describe our initial experience of RPLRN using an umbilical zigzag skin incision for renal cell carcinoma (RCC). A 64-year-old female [body mass index (BMI): 20.0 kg/m
2 ] was diagnosed with right RCC, which was 35 mm in diameter (clinical T1aN0M0). Case 2: a 68-year-old male (BMI: 23.2 kg/m2 ) was diagnosed with right RCC, which was 58 mm in diameter (clinical T1bN0M1), and perinephric fat was relatively thick. The procedure was safely completed in both cases. Total operative times, pneumoperitoneal times, and estimated blood loss in Case 1 and 2 were 90 and 145 min, 49 and 90 min, and 5 and 80 ml, respectively, and the times required to construct umbilical ports and close umbilical wounds were 8 and 9 min and 33 and 46 min, respectively. In Case 1, the specimen was easily extracted without the extension of the umbilical skin incision, whereas it was extended by an additional 2 cm in Case 2. The umbilical wound was inconspicuous in both cases. RPLRN using an umbilical zigzag skin incision for RCC was safely performed without complications, and clashing between instruments was minimized. The high level of cosmesis is advantageous and an umbilical zigzag skin incision may contribute to more widespread use of RPLRN for RCC; however, further studies on long-term oncological outcomes are needed., Competing Interests: Conflict of interestThe authors declare that they have no conflicts of interest., (© The Japan Society of Clinical Oncology 2020.)- Published
- 2020
- Full Text
- View/download PDF
136. Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer.
- Author
-
Kobayashi T, Kanao K, Araki M, Terada N, Kobayashi Y, Sawada A, Inoue T, Ebara S, Watanabe T, Kamba T, Sumitomo M, Nasu Y, and Ogawa O
- Subjects
- Aged, Comorbidity, Humans, Japan, Male, Middle Aged, Patient Selection, Prostatectomy statistics & numerical data, Prostatectomy trends, Prostatic Neoplasms epidemiology, Retrospective Studies, Robotic Surgical Procedures statistics & numerical data, Prostatectomy methods, Prostatic Neoplasms surgery, Robotic Surgical Procedures methods
- Abstract
Background: Introducing a new surgical technology may affect behaviors and attitudes of patients and surgeons about clinical practice. Robot-assisted laparoscopic radical prostatectomy (RALP) was approved in 2012 in Japan. We investigated whether the introduction of this system affected the treatment of organ-confined prostate cancer (PCa) and the use of radical prostatectomy (RP)., Methods: We conducted a retrospective multicenter study on 718 patients with clinically determined organ-confined PCa treated at one of three Japanese academic institutions in 2011 (n = 338) or 2013 (n = 380). Two patient groups formed according to the treatment year were compared regarding the clinical characteristics of PCa, whether referred or screened at our hospital, comorbidities and surgical risk, and choice of primary treatment., Results: Distribution of PCa risk was not changed by the introduction of RALP. Use of RP increased by 70% (from 127 to 221 cases, p < 0.0001), whereas the number of those undergoing radiotherapy or androgen deprivation therapy decreased irrespective of the disease risk of PCa. Increased use of RP (from 34 to 100 cases) for intermediate- or high-risk PCa patients with mild perioperative risk (American Society of Anesthesiologists score 2) accounted for 70% of the total RP increase, whereas the number of low- or very low-risk PCa patients with high comorbidity scores (Charlson Index ≥ 4) increased from 8 to 25 cases, accounting for 18%. Use of expectant management (active surveillance, watchful waiting) in very low-risk PCa patients was 15% in 2011 and 12% in 2013 (p = 0.791)., Conclusions: Introduction of a robotic surgical system had little effect on the risk distribution of PCa. Use of RP increased, apparently due to increased indications in patients who are candidates for RP but have mild perioperative risk. Although small, there was an increase in the number of RPs performed on patients with severe comorbidities but with low-risk or very low-risk PCa.
- Published
- 2018
- Full Text
- View/download PDF
137. Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma.
- Author
-
Nakamura K, Saiki H, Muramatsu H, Morinaga S, Kobayashi I, Kajikawa K, Nishikawa G, Kato Y, Watanabe M, Kanao K, and Sumitomo M
- Abstract
A 61-year-old woman with metastatic renal carcinoma was treated with axitinib as a second-line tyrosine kinase inhibitor. Thirteen days after the treatment, the patient developed reversible posterior leukoencephalopathy syndrome (RPLS). Her symptoms and imaging findings resolved after withdrawal of axitinib, blood pressure control, and administration of glycerin and levetiracetam. RPLS should be kept in mind as a possible rare adverse event after axitinib administration., Competing Interests: All authors declare that they have no competing interest.Informed consent was obtained from the patient including this report.
- Published
- 2017
- Full Text
- View/download PDF
138. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
- Author
-
Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, and Oya M
- Subjects
- Aged, Antineoplastic Agents therapeutic use, Databases, Factual, Everolimus therapeutic use, Female, Humans, Indoles therapeutic use, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Pyrroles therapeutic use, Retrospective Studies, Sunitinib, Survival Analysis, Treatment Outcome, Antineoplastic Agents administration & dosage, Carcinoma, Renal Cell drug therapy, Everolimus administration & dosage, Indoles administration & dosage, Kidney Neoplasms drug therapy, Pyrroles administration & dosage
- Abstract
Background: Relative dose intensity (RDI) is a simple index for evaluation of the amount of drug administered per unit time. We retrospectively investigated the prognostic impact of RDI for patients with metastatic renal cell carcinoma (mRCC) treated with second-line targeted therapy., Methods: We enrolled 168 patients with mRCC. We assessed RDI at 4 weeks after second-line targeted therapy induction., Results: The median follow-up after second-line targeted therapy was 18.1 months. The median time-to-treatment-failure (TTF) and overall survival (OS) were 4.9 and 25.4 months, respectively. In the Kaplan-Meier analysis, the median OS of patients with second-line RDI < 0.7 was significantly shorter than those with RDI ≥ 0.7 (12.1 vs. 31.3 months; P = .030). In the subgroup analysis, second-line RDI was definitely prognostic in the poor-risk group of the International Metastatic Renal Cell Carcinoma Database Consortium criteria, showing second-line RDI was an independent predictor for both TTF (hazard ratio [HR], 3.6; 95% confidence interval [CI], 1.6-8.0; P = .002) and OS (HR, 3.1; 95% CI, 1.1-8.4; P = .026). Also, assessing the type of second-line regimen, the multivariate analysis showed that second-line RDI was an independent prognostic indicator of TTF (HR, 1.7; 95% CI, 1.0-2.9; P = .040) and OS (HR, 2.7; 95% CI, 1.3-5.7; P = .009) in patients treated with everolimus. In this group, the median TTF and OS of patients with RDI < 0.7 were 2.4 and 11.1 months, and those with RDI ≥ 0.7 were 5.3 and 25.9 months, respectively., Conclusion: The results suggest that second-line RDI may be a prognostic predictor for patients with mRCC treated with second-line targeted therapy, particularly in both the International Metastatic Renal Cell Carcinoma Database Consortium poor-risk group and everolimus-treated group., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
139. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.
- Author
-
Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, and Oya M
- Abstract
Background: Two risk models, the Memorial Sloan Kettering Cancer Center (MSKCC) model and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model, have been studied in metastatic renal cell carcinoma (mRCC) treated with targeted therapy., Objective: To validate externally the predictive accuracies of the MSKCC and IMDC models for prognosis in mRCC patients treated with first-line and subsequent second-line targeted therapy., Design, Setting, and Participants: A total of 311 patients were assessed retrospectively., Intervention: All patients underwent targeted therapy., Outcome Measurements and Statistical Analysis: Survival outcomes were assessed using Kaplan-Meier analysis. The predictive ability was evaluated using the c-index., Results and Limitations: Regarding to the first-line targeted therapy, the 3-yr overall survival (OS) rates of the MSKCC (p<0.001) and IMDC models (p<0.001) were 76.2% and 77.3%, respectively, in the favorable-risk group; 46.7% and 47.9%, respectively, in the intermediate-risk group; and 13.4% and 15.6%, respectively, in the poor-risk group. The c-indexes were 0.68 for the MSKCC model and 0.69 for the IMDC model in a first-line setting. Regarding the second-line targeted therapy, the 1-yr OS rates of the MSKCC (p<0.001) and IMDC models (p<0.001) were 80.9% and 90.5%, respectively, in the favorable-risk group; 71.4% and 70.6%, respectively, in the intermediate-risk group; and 31.7% and 24.6%, respectively, in the poor-risk group. The c-indexes were 0.66 for the MSKCC model and 0.65 for the IMDC model in the second-line setting. The study is limited by its retrospective nature., Conclusions: The results may assist physicians in providing more appropriate patient counseling and imply the need for a future prognostic tool in mRCC treated with targeted therapy., Patient Summary: Both risk models were useful for the risk stratification in metastatic renal cell carcinoma (mRCC) patients treated with first-line and second-line targeted therapy; however, it might be necessary to further update or optimize the models for our Japanese cohort of mRCC patients., (Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
140. Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.
- Author
-
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, and Oya M
- Abstract
Background: Previous studies showed the prognostic impact of preoperative levels of neutrophil-to-lymphocyte ratio (NLR), plasma fibrinogen, and serum C-reactive protein (CRP) in surgically treated upper tract urothelial carcinoma; however, few papers have discussed the proper use of these indices., Objective: To investigate whether combinations of these three markers, as a cumulative marker score (CMS), improve the accuracy of prognostic models following radical nephroureterectomy (RNU)., Design, Setting, and Participants: A total of 394 patients from multiple institutions were included. Median follow-up was 30 mo., Intervention: All patients underwent RNU without neoadjuvant chemotherapy., Outcome Measurements and Statistical Analysis: Associated outcomes were assessed using multivariate analysis. The CMS was defined as the number of elevated levels of preoperative NLR, plasma fibrinogen, and serum CRP., Results and Limitations: Multivariate analyses revealed that an increasing CMS was independently associated with high rates of disease recurrence, cancer-specific mortality, and all-cause mortality following RNU. Addition of the CMS to a model that included standard clinicopathologic predictors significantly improved predictive accuracy by 2.7% for disease recurrence, 3.9% for cancer-specific mortality, and 4.0% for all-cause mortality, which were the highest among other prognostic models using each marker alone or combinations of two. The study is limited by its retrospective nature., Conclusions: Although the use of each inflammatory marker alone may be as predictive as clinicopathologic indices for prognosis, combinations like CMS can provide more accurate prognostic models following RNU., Patient Summary: Elevation of blood-based inflammatory markers may be useful for predicting prognosis because of their low cost and accessibility. Among blood-based indices, we examined the efficacy of preoperative neutrophil-to-lymphocyte ratio, plasma fibrinogen, and serum C-reactive protein levels. Although use of each marker alone provides additional prognostic information, the combination of all three markers would be more predictive than any single marker or combinations of two., (Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
141. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
- Author
-
Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, and Oya M
- Subjects
- Aged, Carcinoma, Transitional Cell surgery, Chemotherapy, Adjuvant, Humans, Japan, Kidney Neoplasms surgery, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome, Ureteral Neoplasms surgery, Antineoplastic Agents therapeutic use, Carcinoma, Transitional Cell drug therapy, Kidney Neoplasms drug therapy, Ureteral Neoplasms drug therapy
- Abstract
Purpose: Current guidelines do not yet provide any recommendations for adjuvant chemotherapy in patients with upper tract urothelial carcinoma managed with radical nephroureterectomy. We evaluated whether an adjuvant chemotherapeutic regimen would affect the clinical outcome in patients with high risk upper tract urothelial carcinoma., Materials and Methods: We identified 873 patients who had undergone radical nephrouretectomy for localized upper tract urothelial carcinoma at 14 Japanese institutions between 1993 and 2011. We assessed whether the type of regimen, such as methotrexate, vinblastine, doxorubicin and cisplatin, and gemcitabine and cisplatin, in an adjuvant setting, could affect the subsequent clinical outcome of patients with upper tract urothelial carcinoma., Results: On multivariate analysis pathological T stage, tumor grade, lymphovascular invasion and lymph node involvement were prognostic factors for recurrence-free survival and cancer specific survival. We defined 229 patients with 3 or more of these factors as the high risk group. In an analysis according to adjuvant regimen, Kaplan-Meier curves showed that the 1 and 2-year recurrence-free survival rates in the methotrexate, vinblastine, doxorubicin and cisplatin treated group were 71.4% and 47.9%, which were significantly higher than in the gemcitabine and cisplatin treated group (48.2% and not reached, p=0.022) or those not treated with adjuvant chemotherapy (53.4% and 39.6%, p=0.039). Similar results were observed in terms of cancer specific survival., Conclusions: Our study showed that pT3-4, tumor grade 3, positive lymphovascular invasion and lymph node involvement were independent risk factors for disease mortality in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. In the high risk group methotrexate, vinblastine, doxorubicin and cisplatin adjuvant chemotherapy contributed to improve subsequent mortality compared to gemcitabine and cisplatin or no adjuvant chemotherapy., (Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
142. [A case of neuroendocrine carcinoma in a diverticulum of the bladder].
- Author
-
Muramatsu H, Kanao K, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, Yoshizawa T, Kato Y, Watanabe M, Zennami K, Nakamura K, and Sumitomo M
- Subjects
- Aged, Cystectomy, Diverticulum surgery, Female, Humans, Magnetic Resonance Imaging, Neoplasm Invasiveness, Urinary Bladder Neoplasms surgery, Carcinoma, Neuroendocrine surgery, Diverticulum pathology, Urinary Bladder Neoplasms pathology
- Abstract
We report a case of neuroendocrine carcinoma in a diverticulum of the bladder. A 65-year-old Japanese woman visited our hospital with the chief complaint of gross hematuria. Cystoscopy revealed a non-papillary broad-based tumor in a diverticulum of the posterior wall. She underwent transurethral resection of bladder tumor (TURBT) and subsequently total cystectomy with ileal conduit on the diagnosis of an invasive urothelial carcinoma. There was no residual tumor in the surgical specimen. Immunohistochemistry of TUR specimens showed positive synaptophysin, chromogranin A, CD56 and high ratio of positive Ki-67. Finally, it was diagnosed as a neuroendocrine carcinoma of the bladder. To our knowledge, this is the second case report of the neuroendocrine tumor or small cell carcinoma in a diverticulum of the urinary bladder in the Japanese literature.
- Published
- 2014
143. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
- Author
-
Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, and Murai M
- Subjects
- Albumins metabolism, Animals, Antineoplastic Agents pharmacology, Benzamides chemistry, Body Mass Index, Body Weight, Cell Line, Tumor, Cyclohexanones chemistry, Disease Models, Animal, Dose-Response Relationship, Drug, Hematocrit, Humans, Interleukin-6 biosynthesis, Interleukin-6 blood, Interleukin-6 metabolism, Male, Mice, Mice, Inbred BALB C, Muscle, Skeletal drug effects, Neoplasm Transplantation, Time Factors, Triglycerides blood, Weight Loss drug effects, Benzamides pharmacology, Cachexia prevention & control, Cyclohexanones pharmacology, NF-kappa B antagonists & inhibitors, Prostatic Neoplasms complications, Prostatic Neoplasms drug therapy
- Abstract
Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the inhibitory effect of a new nuclear factor kappaB (NF-kappaB) inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on IL-6 production and cachexia in an animal model of hormone-refractory prostate cancer., Experimental Design: The association between serum IL-6 levels and variables of cachexia was evaluated in 98 patients with prostate cancer. The inhibitory effects of DHMEQ on IL-6 secretion and cachexia were investigated in in vitro and in vivo studies using JCA-1 cells derived from human prostate cancer., Results: Serum IL-6 levels were significantly elevated and cachexia developed in JCA-1 tumor-bearing mice as well as in prostate cancer patients with progressive disease. IL-6 secretion was significantly inhibited in JCA-1 cells exposed to DHMEQ. Intraperitoneal administration of DHMEQ (8 mg/kg) to tumor-bearing mice produced a significant amelioration of the reduction in body weight, epididymal fat weight, gastrocnemius muscle weight, hematocrit, and serum levels of triglyceride and albumin when compared with administration of DMSO or no treatment. DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P < 0.05)., Conclusions: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-kappaB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion. DHMEQ seems to show promise as a novel and unique anticachectic agent in hormone-refractory prostate cancer.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.